Non-motor Effects of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study (P9-3.001)Harini Sarva, Viviane Tabar, Claire Henchcliffe et al.|Neurology|2024Cited by 0
Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study (P9-3.007)Claire Henchcliffe, Viviane Tabar, Harini Sarva et al.|Neurology|2024Cited by 0
Imaging Outcomes of a Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: 18-month Results from a Phase 1 Study of Bemdaneprocel (S30.005)Claire Henchcliffe, David Eidelberg, Kenny Yu et al.|Neurology|2024Cited by 0